Health & Wellness

Press Releases

Rafael Pharmaceuticals, in Collaboration with Atlantic Health System, Announces Initiation of a Phase I Study of CPI-613 in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic Cancer

Rafael Pharmaceuticals, Inc., a clinical stage company and leader in the field of cancer metabolism-based therapeutics, announced today, the initiation of a Phase I clinical trial of CPI-613 in combination with chemotherapeutic agents, gemcitabine and nab-paclitaxel, for patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in collaboration with Atlantic Health System. CPI-613 is a first-in-class drug with a unique mode of action and is Rafael’s lead altered energy metabolism directed (AEMD) drug candidate. The drug is designed to disrupt the altered energy-production pathways in cancer cells by targeting their mitochondrial metabolism.

The primary aim of the study is to establish the maximum tolerated dose of CPI-613 when given in combination with gemcitabine/nab-paclitaxel for patients with locally advanced or metastatic pancreatic cancer.

Secondary aims include:

Sign Up for E-News

(1) To describe the safety profile for the gemcitabine/nab-paclitaxel/CPI-613 combination.
(2) To determine the clinical activity of gemcitabine/nab-paclitaxel/CPI-613 in metastatic pancreatic cancer as measured by tumor response rate (RR) by RECIST criteria, progression-free survival (PFS), and overall survival (OS).

Encouraging results observed in earlier trials, including Phase I data from a trial led by Angela Alistar, MD that was recently published in The Lancet Oncology, demonstrated the preliminary efficacy of CPI-613 in combination with modified FOLFIRINOX (a multidrug treatment for advanced pancreatic cancer) in patients with metastatic pancreatic cancer. These results support further evaluation of CPI-613 in this indication.[1] The safety profile of CPI-613 in earlier trials, which shows the drug to be well tolerated, provides further support for evaluation of CPI-613 in combination with other drugs to maximize benefit.

In 2013, the MPACT study, a multinational, phase III clinical trial comparing gemcitabine/nab-paclitaxel to gemcitabine alone, demonstrated an improved median survival of 8.5 months as compared with 6.7 months for gemcitabine monotherapy (p=0.000015). While some clinical benefit was shown, these outcomes also highlight the need for new combination strategies to improve upon the outcomes seen with gemcitabine/nab-paclitaxel in the treatment of metastatic pancreatic cancer.

Dr. Alistar, medical director of GI Medical Oncology at the Carol G. Simon Cancer Center of Morristown Medical Center, Atlantic Health System, and the Principal Investigator for this trial, remarked, “Strategies to enhance our current standard of care options are sorely needed in pancreatic cancer. Due to the low toxicity profile of CPI -613 as a single agent, I anticipate good tolerance in combination with the gemcitabine/nab-paclitaxel regimen. I am excited to be able to offer this novel option to our patients with pancreatic cancer. Targeting metabolism in pancreatic cancer has a strong scientific rationale.”

Sanjeev Luther, Rafael Pharmaceuticals’ Chief Executive Officer, commented, “Our company’s motto of “One Patient at a Time” is especially relevant in this situation. Patients with a low tolerance for toxicity may not be eligible for the FOLFIRINOX combo. We believe that the gemcitabine/nab-paclitaxel regimen has the potential to be a potent treatment with less toxicity. It is especially meaningful for us to announce the initiation of this study on World Pancreatic Cancer Day.”

About Atlantic Health System

Atlantic Health System, headquartered in Morristown, N.J., is an integrated health care delivery system powered by a workforce of 16,000 team members dedicated to building healthier communities. The system is comprised of 350 sites of care, including six hospitals: Morristown Medical Center, Overlook Medical Center, Newton Medical Center, Chilton Medical Center, Hackettstown Medical Center and Goryeb Children’s Hospital. Atlantic Health System also supports communities through Atlantic Medical Group, Atlantic Rehabilitation, Atlantic Home Care and Hospice, and its subsidiary, Atlantic Ambulance Corporation. Atlantic Health System sponsors the Atlantic Accountable Care Organization, one of the larger ACOs in the nation, and Optimus Healthcare Partners. 

 

About Rafael Pharmaceuticals, Inc.

Rafael Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael’s primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Rafael’s first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613 an orphan drug for the treatment of pancreatic cancer, AML, and myelodysplastic syndromes (MDS). The company's investors include IDT Corporation (NYSE: IDT). For more information, visit http://www.rafaelpharma.com/.

 

Safe Harbor Statement

This press release contains forward-looking statements. These statements relate to future events or the company’s future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Reference

[1] Alistar A, Morris BB, Desnoyer R, et al. (2017). Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. The Lancet Oncology. doi: 10.1016/S1470-2045(17)30314-5.

TAP Into Another Town's News:

You May Also Be Interested In

Sign Up for E-News

Sparta

Sparta Police: Traffic Stop Yields Hundreds of Empty Heroin Packets

December 7, 2017

SPARTA, NJ – A Long Valley resident was found to have hundreds of empty wax packets used to hold heroin when he was stopped for having an expired inspection sticker.  Sparta Police Officer Thomas Snyder stopped a gray Honda Accord on December 4 around 9:50 a.m. on Route 15, police report.

When Snyder went to speak with Daniel Gaeta, 30, the driver told the officer he was being ...

Sparta Police: Vernon Man Hits a Curb, Gets DWI

SPARTA, NJ – A Vernon man has been charged with driving while intoxicated after he hit a curb and disabled his Jeep.  On November 30 around 11;20 p.m. Sparta Police Officer Ericks Finley found the Robert Houdershieldt, 44, sitting in his Grand Cherokee on the Route 15 southbound ramp, police say.

When Finley spoke with the driver, Houdershieldt told the officer he was on the phone ...

Sparta Police: Wanted Orange Man Picked Up After Driving Erratically

SPARTA, NJ – An Orange resident is in custody on outstanding warrants and other charges after getting stopped by Sparta police on Woodport Road.  On November 21 around 1:40 a.m. Sparta Police Officer Thomas Snyder stopped an Audi driven by Damani Weekes, police say.

According to police Weekes was driving erratically, crossing over the yellow line several times.  When Snyder ...

Obituaries

- Jun 2, 2017
Jillian Mari Baluyot, 17, of Nutley, passed away on June 2, 2017. Born in Secaucus, she lived in ...
Read more
- Feb 21, 2017
Marisa Rincon (30) passed away in Randolph on February 21,2017. She was born is West Chester, PA ...
Read more

Thanks for Saving my House

December 10, 2017

It was strange to get a phone message at a local movie theater that my house was on fire in Lake Stockholm on Friday. It was thirty years ago that I had a house fire in the same community, but tonight I was at the AMC movie in Rockaway getting a call about my house again being on fire. I arrived in Lake Stockholm to see the firemen keeping damage to a minimum!

Without the great effort of ...

Upcoming Events

Wed, December 13, 12:00 PM

Stanhope

Top Notch Resume I: The Basics

Business & Finance

Thu, December 14, 10:00 AM

Sparta Ambulance Building, Sparta

Sparta Friends and Neighbors Holiday Charity ...

Giving Back

Wed, December 20, 12:00 PM

Stanhope

Top Notch Resume II: Advanced

Business & Finance

Fri, January 12, 12:00 PM

Rutgers/Douglass Student Center, New Brunswick

North Jersey Orchid Society 51st Annual Orchid ...

Fri, January 12, 12:00 PM

Rutgers/Douglass Student Center, New Brunswick

North Jersey Orchid Society 51st Annual Orchid ...

Arts & Entertainment Education Home & Garden

AtlantiCast: Episode 008

On this week’s AtlantiCast, you’ll learn about a groundbreaking new clinical trial in the fight against pancreatic cancer, meet an award-winning child neurologist at Goryeb Children’s Hospital and hear about the new Scoliosis and Spinal Deformity Center at Atlantic Orthopedic Institute – plus stay tuned at the end to see our debut episode of the AtlantiCast Medical ...

Two Elizabeth Residents Arrested in Massive Child Trafficking and Pornography Sting

December 1, 2017

TRENTON, NJ – Arrests have been made in a massive operation that stretched from New Jersey to California, that targeted sex offenders, and persons possessing child pornography was announced today by Attorney General Christopher S. Porrino.

Arrests of 79 child predators and child pornography offenders in “Operation Safety Net,” a nine-month, multi-agency child protection ...

Celebrate the Season at Sparta’s 16th Annual Lake Mohawk German Christmas Market

Don’t miss this weekend’s 2017 Weihnachtsmarkt: 16th Annual Lake Mohawk German Christmas Market at Lake Mohawk in Sparta!  

Ranked as “One of the Top Ten Things to Do in December in the State”, this market offers 100+ vendors selling beautifully-crafted and unique gifts; delicious food & drink; live entertainment (from folk dancers to carolers to chainsaw wood ...

Are your medications interacting with one another? For the health of it, find out!

A national poll of almost 1700 people age 50 - 80 conducted by researchers at the University of Michigan Institute for Health Care Policy found that only a third of them who take at least one prescription drug had talked to a health care professional about drug interactions in the previous two years. Among those taking six or more medications, less than half had talked with a health care ...

I Love America Poster Contest Announced by Project Help

December 11, 2017

SUSSEX, NJ – “I Love America” poster contest

Project Help a local charity devoted to helping veterans, is hosting their first annual Poster contest for students all over New Jersey. 

The theme is “I Love America” and open to all budding young artists.  Prizes will be awarded in each category grade category and will be judged on design, originality and ...